An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13

Vaccine

Volumn 33, Issue 9, 2015, Pages 1102-1106

  Wohlbold, Teddy John ^a   Hirsh, Ariana ^a   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Avian influenza; Emerging viruses; H10N7, Influenza vaccine; H10N8; Influenza virus

Indexed keywords

GLYCOPROTEIN; H10N8 INFLUENZA VIRUS VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; UNCLASSIFIED DRUG; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NA PROTEIN, INFLUENZA A VIRUS; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EMBRYO; ERYTHROCYTE; INFLUENZA VIRUS A H10N8; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIROGENESIS; VIRUS INACTIVATION; ZYGOTE; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CHINA; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H10N8); ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL;

ANIMALS; BODY WEIGHT; CHINA; DISEASE MODELS, ANIMAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H10N8 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84945575320     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.026     Document Type: Article

References (20)

1. Chen H., Yuan H., Gao R., Zhang J., Wang D., Xiong Y., et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014, 383:714-721.
2. 〈http://www.wpro.who.int/china/mediacentre/factsheets/h10n8/en/〉.
3. Su S., Qi W., Zhou P., Xiao C., Yan Z., Cui J., et al. First evidence of H10N8 avian influenza virus infections among feral dogs in live poultry markets in Guangdong Province, China. Clin Infect Dis 2014, 59:748-750.
4. García-Sastre A., Schmolke M. Avian influenza A H10N8-a virus on the verge?. Lancet 2014, 383:676-677.
5. Qi W., Zhou X., Shi W., Huang L., Xia W., Liu D., et al. Genesis of the novel human-infecting influenza A(H10N8) virus and potential genetic diversity of the virus in poultry, China. Eurosurveillance 2014, 19. pii: 20841.
6. Ni X., He F., Hu M., Zhou X., Wang B., Feng C., et al. Investigation of avian influenza virus in poultry and wild birds due to novel avian-origin influenza A(H10N8) in Nanchang City, China. Microbes Infect 2015, 17:48-53.
7. Qi W., Su S., Xiao C., Zhou P., Li H., Ke C., et al. Antibodies against H10N8 avian influenza virus among animal workers in Guangdong Province before November 30, 2013, when the first human H10N8 case was recognized. BMC Med 2014, 12:205.
8. Beare A.S., Schild G.C., Craig J.W. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet 1975, 2:729-732.
9. Rodriguez A., Pérez-González A., Hossain M.J., Chen L.M., Rolling T., Pérez-Breña P., et al. Attenuated strains of influenza A viruses do not induce degradation of RNA polymerase II. J Virol 2009, 83:11166-11174.
10. Matsuoka Y., Chen H., Cox N., Subbarao K., Beck J., Swayne D. Safety evaluation in chickens of candidate human vaccines against potential pandemic strains of influenza. Avian Dis 2003, 47:926-930.
11. Campbell P.J., Danzy S., Kyriakis C.S., Deymier M.J., Lowen A.C., Steel J. The M segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to A/Puerto Rico/8/1934-based reassortant viruses. J Virol 2014, 88:3802-3814.
12. Krammer F., Albrecht R.A., Tan G.S., Margine I., Hai R., Schmolke M., et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol 2014, 88:3976-3985.
13. Klausberger M., Wilde M., Palmberger D., Hai R., Albrecht R.A., Margine I., et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014, 32:355-362.
14. Margine I., Palese P., Krammer F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 2013, e51112. 10.3791/51112.
15. Tan G.S., Lee P.S., Hoffman R.M., Mazel-Sanchez B., Krammer F., Leon P.E., et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin. J Virol 2014, 88:13580-13592.
16. Arzey G.G., Kirkland P.D., Arzey K.E., Frost M., Maywood P., Conaty S., et al. Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg Infect Dis 2012, 18:814-816.
17. Friesen R.H., Lee P.S., Stoop E.J., Hoffman R.M., Ekiert D.C., Bhabha G., et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 2014, 111:445-450.
18. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850.
19. Dreyfus C., Laursen N.S., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D.C., et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348.
20. Couzens L., Gao J., Westgeest K., Sandbulte M., Lugovtsev V., Fouchier R., et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 2014, 210C:7-14.